DNA *O*^6^-alkylguanine lesions are mutagenic and cytotoxic: they mis-pair during replication with thymine, resulting in G:C to A:T transition mutations[@R1]--[@R4]. Human *O*^6^-alkylguanine DNA lesions are repaired by *O*^6^-alkylguanine-DNA alkyltransferase (AGT), also known as *O*^6^-methylguanine-DNA methyltransferase (MGMT), which transfers guanine *O*^6^-alkyl adducts to its reactive cysteine reversing damage[@R1]. This prevents mutations but resists alkylating chemotherapies[@R2],[@R5]. Active site -PCHRV- motif Cys145[@R6],[@R7] plus Arg128 and Tyr114 nucleotide rotating residues are conserved from bacterial to human AGTs[@R1],[@R2],[@R8]. Human AGT (hAGT) structures alone[@R9],[@R10] and with small molecule[@R9] or DNA[@R11],[@R12] substrates showed how AGT promotes resistance to anticancer therapies by directly reversing DNA guanine alkylation damage.[@R2]

Recently bacterial and yeast proteins with sequence similarity to the AGT DNA-binding domain were identified with the Cys alkyl acceptor replaced by tryptophan, alanine, or another residue,[@R13] and hence named alkyltransferase-like proteins (ATLs). ATLs from *S. pombe* (Atl1) and *E. coli* (eAtl) inhibit *O*^6^-methylguanine (*O*^6^-mG) repair by hAGT[@R14],[@R15]. eAtl also binds abasic site-containing dsDNA,[@R16] and Atl1 binds ssDNA containing *O*^6^-methyl-, *O*^6^-benzyl-, *O*^6^-(4-bromothenyl)- or *O*^6^-hydroxyethyl-guanine. Yet, ATLs do not cleave the alkyl group, base, or oligonucleotide near the lesion[@R14],[@R15], and eAtl Trp to Cys mutation does not restore alkyltransferase activity[@R14]. As *S. pombe* and *T. thermophilus* lack AGT, and inactivation of their ATL genes, *atl1* and *TTHA1564*, respectively[@R15],[@R17], reduces their alkylation damage resistance, ATLs protect against biological effects of DNA alkylation damage by an undefined mechanism.

Tight binding affinities[@R16],[@R17] for and inability to repair[@R14],[@R15] *O*^6^-alkyl lesions implied ATLs are damage sensors or act in nucleotide excision repair (NER)[@R13],[@R15], which excises bulky, DNA-distorting lesions. However, lack of structures, persuasive evidence, or specific mechanism has obscured how ATL ameliorates DNA damage effects. To clarify this protection, we combined structural, biochemical, and genetic experiments on Atl1 from the fission yeast *S. pombe*. Our results reveal ATL binding generates a stable complex that sculpts alkylated DNA base damage for NER pathway entry.

Atl1 structure and lesion binding {#S1}
=================================

To characterize Atl1-DNA damage interactions, we crystallized and solved structures to 2.0, 2.7, and 2.8 Å resolution, respectively, for Atl1 alone ([Fig. 1a](#F1){ref-type="fig"} and [Supplementary Table 1](#SD1){ref-type="supplementary-material"}) and in complex with oligonucleotides containing either *O*^6^-mG ([Fig. 1b, d](#F1){ref-type="fig"} and [Supplementary Table 1](#SD1){ref-type="supplementary-material"}) or *O*^6^-4-(3-pyridyl)-4-oxobutylguanine (*O*^6^-pobG) ([Fig. 1c](#F1){ref-type="fig"} and [Supplementary Table 1](#SD1){ref-type="supplementary-material"}), a bulky and toxicologically-relevant adduct[@R18]. Atl1 shares the hAGT catalytic domain fold (superposition root mean square difference = 1.6 Å) ([Fig. 1a](#F1){ref-type="fig"}), including residues required for AGT activity, DNA-binding, and nucleotide flipping. Yet, Atl1 specifically lacks AGT's active site Cys and Asn hinge that couples helix-turn-helix (HTH) DNA binding and active site motifs ([Fig. 1a](#F1){ref-type="fig"}).

Atl1 flips both *O*^6^-mG ([Fig. 1b, d](#F1){ref-type="fig"}) and *O*^6^-pobG ([Fig. 1c](#F1){ref-type="fig"}) into a pocket containing -PWHRV- motif Trp56, consistent with fluorescence measured flipping for a base opposite an AP site in eAtl[@R16] and for *O*^6^-mG in TTHA1564[@R17]. Atl1 displays no AGT activity,[@R15] suggesting nucleotide flipping is a switch for pathway activation, not catalysis. To our knowledge, Atl1 ([Fig. 1b--d](#F1){ref-type="fig"}), eAtl[@R16], and TTHA1564[@R17] are among the first reported non-enzymatic DNA-binding proteins that flip nucleotides. Our Atl1 structures show ATL rotates nucleotides into a specificity pocket. Arg39 intercalates the DNA base stack ([Fig. 1d](#F1){ref-type="fig"}) and hydrogen bonds the orphaned cytosine, thereby stabilizing the extra-helical alkylguanine. Trp56, rather than AGT Cys, is evident in electron density omit maps ([Fig. 1a](#F1){ref-type="fig"}), acting in hydrophobic packing with the alkyl group ([Fig. 1c, d](#F1){ref-type="fig"}). Arg69 guanidinium stacks against the alkylguanine base in a cation-π interaction ([Fig. 1d](#F1){ref-type="fig"}).

Alkylguanine base side and main chain hydrogen bonds are conserved from Atl1 to AGT, but the Atl1 lesion-binding pocket is \~three times larger ([Supplementary Table 2](#SD1){ref-type="supplementary-material"}). Loop residues 65--73 define one wall of the alkyl-binding pocket, adopting a conformation further from the protein core than in AGT, thereby enlarging the pocket ([Fig. 1a](#F1){ref-type="fig"} and [Fig. 2a](#F2){ref-type="fig"}). Also, lesion-binding pocket Lys45-Pro55 cap is \~5.3 Å further out than the comparable AGT Pro140 (Cα to Cα distance) that interacts with larger alkyl groups[@R9],[@R11],[@R12]. Moreover, ATL Ile71 replaces AGT Tyr158, which would clash with the Atl1 Trp56 side chain in its DNA-bound, closed position.

Atl1's larger cavity explains its broad lesion range that includes *O*^6^-benzyl-, *O*^6^-(4-bromothenyl)- or *O*^6^-hydroxyethyl-guanine. In the *O*^6^-pobG-DNA complex structure, the pob group is wedged between Pro50 and Trp56, making only these hydrophobic protein interactions ([Fig. 1c](#F1){ref-type="fig"}). No major changes in lesion-binding site, or DNA conformation occur between *O*^6^-mG- and *O*^6^-pobG-bound Atl1. Pob would push against the active (or binding) site loop in the smaller AGT active site, explaining why AGT repairs pob lesions at a decreased rate compared to *O*^6^-mG[@R19]. Pob adopts a conformation incompatible with smaller *E. coli* AGT (Ada-C and Ogt) active site pockets, consistent with its poor repair by Ada-C and Ogt[@R20] and need for ATLs for bulky adducts in organisms like *E. coli*.

Atl1 DNA-binding {#S2}
================

Like AGT, Atl1 uses an HTH motif to bind the DNA minor groove ([Fig. 1b](#F1){ref-type="fig"} and [Fig. 2a](#F2){ref-type="fig"}). All damaged-strand contacts are to alkylguanine and two 3'-adjacent nucleotide phosphate groups ([Fig. 2d](#F2){ref-type="fig"}). DNA binding site loop (Ser67 and Lys70) and loop (Thr92 and Ser93) residues form DNA contacts not found in AGT. Atl1 DNA-binding buries \~1050 Å^2^ versus 788 Å^2^ of AGT buried surface area, consistent with tighter DNA binding[@R16],[@R17].

Atl1 bends DNA by \~45° ([Fig. 2a](#F2){ref-type="fig"}), whereas AGT only bends DNA \~30°[@R11]. Atl1 achieves greater DNA bending through synergistic N-terminus and binding site loop actions. The Atl1 N-terminal helix extends outward more than the corresponding AGT helix, which follows a loop leading toward the N-terminal domain ([Fig. 1a](#F1){ref-type="fig"} and [Fig. 2a](#F2){ref-type="fig"}). This N-terminal extension pushes against the phosphate backbone of the complementary strand opposite the flipped nucleotide. Moreover, the binding site loop acts as a gate that switches between "open" ([Fig. 2b](#F2){ref-type="fig"}) and "closed" ([Fig. 2c](#F2){ref-type="fig"}) conformations of free and DNA-bound Atl1, respectively, with flanking glycines suggesting flexibility. This "gating" action was proposed in AGT computational simulations[@R21], but not seen in crystal structures[@R11],[@R12]. The Atl1 binding site loop open-to-closed conformational switch appears suitable to play an active role in signalling by shifting covering Arg and Ile side chains to expose the C-terminal loop for possible intermolecular interactions.

If the closed, bent ATL-DNA complex is a platform for repair protein recognition, then we expect the complex to be stable; yet, K~D~ was estimated by gel-shift as only 0.41 µM for TTHA1564 with *O*^6^-mG[@R17]. To test binding affinity, we measured Atl1 binding and dissociation to and from oligonucleotides containing *O*^6^-mG, *O*^6^-pobG, or abasic site by surface plasmon resonance ([Fig. 3a](#F3){ref-type="fig"}). Atl1 binding to oligonucleotides containing alkylG was 0.02--0.3 nM, but binding to abasic site dsDNA was low and/or transient ([Fig. 3a](#F3){ref-type="fig"}). Langmuir fit with mass transfer limitation indicates *k~ass~* = 1.21×10^−7^±0.20×10^−7^ M^−1^s^−1^; *k~diss~* = 0.004 ± 0.0006 s^−1^ and *K~D~* = 0.35 ± 0.04 nM for *O*^6^-mG and *k~ass~* = 2.20×10^−7^± 0.56×10^−7^ M^−1^s^−1^; *k~diss~* = 0.0003 ± 0.00002 s^−1^ and *K~D~* = 0.016 ± 0.004 nM for *O*^6^-pobG. Thus, while "on" rates were similar for both lesions, the "off" rate for pob oligonucleotide was slower: higher affinity (*K~D~*) for the pob oligonucleotide shows larger *O*^6^-alkyl groups are accommodated stably.

We also measured Atl1 binding to methylated double-strand oligonucleotides by gel-shift ([Fig. 3b](#F3){ref-type="fig"} and [Supplementary Fig. 1](#SD1){ref-type="supplementary-material"} and [Supplementary Table 3](#SD1){ref-type="supplementary-material"}) and verified saturated complex stoichiometries by sedimentation equilibrium analysis ([Fig. 3c](#F3){ref-type="fig"} and [Supplementary Table 3](#SD1){ref-type="supplementary-material"}). Dominant complexes for 13-mer oligonucleotides in solution have 1:1 stoichiometry ([Fig. 3b, c](#F3){ref-type="fig"} and [Supplementary Table 3](#SD1){ref-type="supplementary-material"}), consistent with our crystal structures, whereas 16-mers form 2:1 limiting complexes ([Supplementary Fig. 1a](#SD1){ref-type="supplementary-material"} and [Supplementary Table 3](#SD1){ref-type="supplementary-material"}) and 26-mers form 3:1 limiting complexes ([Supplementary Fig. 1b](#SD1){ref-type="supplementary-material"} and [Supplementary Table 3](#SD1){ref-type="supplementary-material"}). Saturated Atl1-nonmethylated DNA complex is formed without intermediate accumulation, suggesting cooperative binding to nonmethylated DNA. DNAs containing *O*^6^-mG form 1:1 complexes before proceeding to saturation in an additional concerted step, suggesting specific binding to *O*^6^-mG sites precedes build-up of cooperative assembly, consistent with the open-to-closed switch and a binding site size of \~8 bp. This differs from AGT's binding site size of 4 bp/protein[@R22], possibly due to AGT\'s added N-terminal domain and the open-to-closed switch (not seen in AGT) that exposes the C-terminal loop.

Atl1 connections to NER {#S3}
=======================

ATLs tightly bind oligonucleotides containing *O*^6^-alkylguanine and switch conformation to expose the C-terminal loop, suggesting ATL-DNA complex binding partners are possible, *in vivo*. In fact, NER protein UvrA interacts with TTHA1564[@R17]. Similarly, far-western analysis reveals eAtl interacts with *E. coli* NER proteins UvrA and UvrC *in vitro* ([Fig. 4a](#F4){ref-type="fig"}). *E. coli* DNA repair helicase IV (HelD) is also a potential eAtl binding partner[@R16]. Interestingly, *S. pombe* Atl1 interacts with *E. coli* UvrA *in vitro* ([Fig. 4b](#F4){ref-type="fig"}), suggesting ATLs conserve features across species for NER recognition.

To test for Atl1 functional genetic interactions with the NER pathway in fission yeast, we analyzed *S. pombe atl1* and *rad13* (NER pathway XPG endonuclease human homolog which cuts 3\' of DNA lesions[@R23]) single and double deletants. We measured Atl1's ability to protect cells from MNNG-induced and spontaneous mutations ([Fig. 4c--e](#F4){ref-type="fig"}). MNNG sensitivity of Δ*atl1* cells was complemented by a plasmid harbouring *atl1* ([Supplementary Fig. 2](#SD1){ref-type="supplementary-material"}), indicating observed cellular phenotypes are due to *atl1* deletion. Atl1 inactivation causes \~9-fold increased reversion rate of the *ade6-485* mutation, similar to the Δ*rad13* mutant ([Fig. 4c](#F4){ref-type="fig"} top). The MNNG-induced mutation rate is not further increased in the Δ*atl1* Δ*rad13* double mutant, revealing an epistatic relationship between Atl1 and Rad13 ([Fig. 4c](#F4){ref-type="fig"} top). These results are supported by spot tests ([Fig. 4d](#F4){ref-type="fig"}) and clonogenic assays ([Fig. 4e](#F4){ref-type="fig"}) indicating Atl1 and Rad13 are also epistatic for MNNG toxicity.

Strikingly, increased spontaneous mutation rate of Δ*rad13* cells is suppressed to wild-type levels by additional Atl1 inactivation ([Fig. 4c](#F4){ref-type="fig"} bottom). This effect is not due to decreased cell survival, as all mutants tested here are viable ([Supplementary Fig. 3](#SD1){ref-type="supplementary-material"}). Clonogenic assays also revealed Atl1 is epistatic with *S. pombe* Swi10 ([Fig. 4f](#F4){ref-type="fig"}), but not Rhp14 ([Fig. 4g](#F4){ref-type="fig"}) or Rad2 ([Fig. 4h](#F4){ref-type="fig"}) (homologs of human ERCC1, XPA and Fen-1, respectively), for MNNG toxicity. The non-epistatic relationship between Atl1 and Rhp14 suggests Rhp14 has an NER-independent function in response to MNNG, consistent with Rhp14 responses to other DNA damaging agents (R.K. and O.F., unpublished data). As Rad2 plays a role in long-patch base excision repair (BER)[@R24] and the alternative UV excision repair[@R25], lack of epistasis between *atl1* and *rad2* implies the two proteins work in different pathways. *Rad13* and *swi10* mutant phenotypes may reflect build-up of stable hard-to-repair ATL-complex intermediates in the absence of these NER proteins, suggesting ATL-DNA complexes may block alternative repair. Similarly, Atl1 protects *E. coli* cells against MNNG-induced alkylation damage ([Supplementary Table 4](#SD1){ref-type="supplementary-material"}). Thus, both microbial and eukaryotic genetic evidence suggests ATL bridges DNA-alkylation base damage responses to NER.

Identification of novel ATLs {#S4}
============================

To see if our structures may characterize other ATLs, we mapped sequence conservation of 197 ATL sequences based upon the Atl1 structure ([Supplementary Fig. 4](#SD1){ref-type="supplementary-material"} and [Supplementary Fig. 5](#SD1){ref-type="supplementary-material"}). For all ATLs, the most conserved residues line the lesion-binding pocket or act in DNA binding in our structures, suggesting our Atl1 structures are paradigmatic for ATLs.

Significantly, our structure-based sequence analyses helped us identify here the first ATL from any multicellular organism, the recently sequenced starlet sea anemone *Nematostella vectensis*[@R26] plus two archaeal ATLs from *Candidatus* Korarchaeum cryptofilum[@R27] and *Nanoarchaeum equitans*[@R28], ancestral to the two established phyla of archaea (Genbank accession numbers XM_001618690, YP_001736655, and NP_963633, respectively; [Supplementary Fig. 4](#SD1){ref-type="supplementary-material"} and [Supplementary Fig. 6](#SD1){ref-type="supplementary-material"}). We verified *N. vectensis* ATL blocks alkyltransferase activity of hAGT ([Supplementary Fig. 7](#SD1){ref-type="supplementary-material"}), confirming it is an ATL. The *N. vectensis* genome, which aided in genome characterization of the long-extinct last common ancestor of all eumetazoans, is surprisingly more similar to vertebrates than fruit flies or nematodes[@R26]. Therefore, existence of ATL in this multi-cellular eukaryote, plus yeast, bacteria, and ancestral archaea shows ATL is present in all three domains of life and argues ATL was common to evolutionary branches before complex eukaryotes. This discovery suggests higher eukaryotes and mammals will either have an ATL or have lost or replaced it with an analogous protein.

Discussion {#S5}
==========

Alkylated DNA base damage is classically repaired by direct damage reversal proteins or by lesion-specific DNA glycosylases, which excise modified bases to create abasic sites and initiate the BER pathway[@R29]. These base repair processes differ from the versatile NER removal of bulky, unrelated, helix distorting lesions by excising a lesion-containing DNA patch[@R30]. Our combined results reveal a general mechanism for ATL to bind weakly distorting *O*^6^-alkylguanine lesions and recruit NER proteins ([Fig. 5](#F5){ref-type="fig"}). We propose ATL binding sculpts alkylguanine into a bulky lesion that is channeled into the NER pathway, explaining NER-mediated repair of *O*^6^-alkylguanine lesions[@R31]--[@R33].

ATL may be an unrecognized NER element, with analogues in many organisms, that targets endogenous alkylation damage to NER nucleases. In higher eukaryotes, the NER transcription-coupled repair (TCR) sub-pathway engages downstream damage recognition components of global genome repair (GGR), to effect lesion removal from the transcribed strand[@R34]. The NER GGR sub-pathway is initiated by XPC recognition of bulky lesions and, like TCR, results in damage removal by incision on either side of the lesion[@R35]. As the *O*^6^-mG lesion is insufficient to block transcription[@R36], ATL binding may stall RNA polymerase to initiate TCR and/or promote lesion processing analogously to DDB2 of mammalian GGR. Atl1-DNA contacts are with the damaged strand, similar to DDB2[@R37], consistent with possible undamaged strand binding by fission yeast XPC homologues Rhp41 or Rhp42, as shown for *S. cerevisiae* XPC orthologue, Rad4[@R38].

ATLs are not alkyltransferases[@R14],[@R15],[@R17] or glycosylases[@R14],[@R15], but inhibit AGT[@R14],[@R15] ([Supplementary Fig. 7](#SD1){ref-type="supplementary-material"}). Lack of epistasis for MNNG-induced cell killing between *atl1* and *rad2* shows ATL is not a long-patch BER or alternative UV excision repair protein. Yet, ATL damage recognition resembles AGT and BER glycosylases rather than NER proteins: positive channel for lesion-binding and 180° nucleotide flipping, which allow protein handoffs without release of toxic and mutagenic DNA intermediates, a hallmark of BER and recombination repair pathways[@R39]--[@R43].

ATL binding targets base damage to NER, showing how proteins that bind damage, but do not repair it, may redirect lesion processing.[@R44] First, ATL binds base damage analogously to AGT and BER glycosylases[@R2],[@R45], but presents damage to NER similarly to DDB2. Second, in some organisms ATL can block AGT *O*^6^-alkylguanine damage recognition and redirect base repair to NER, constituting a crosstalk pathway connection,[@R44] as proposed for AGT[@R33],[@R46], and recently for eATL[@R20]. Third, ATL redirects endogenous damage from other repair pathways to NER, as Δ*rad13* mutator is rescued in Δ*atl1* Δ*rad13*. Fourth, ancestral archaeal ATL's are ATL-Endo V fusions, suggesting ATL and Endo V act together in a coordinated pathway[@R47] with BER nuclease Endo V serving a possible XPG-like function in these organisms, as AGT-Endo V fusion proteins retain both activities[@R48]. By the Rosetta Stone evolution hypothesis for protein interactions[@R47], ATL-Endo V fusions imply ATL provides a primordial connection joining BER and NER. Indeed, recent structures of EndoV[@R49] and NER complex DDB1-DDB2[@R37] support such an ancient BER-NER connection by revealing a mutual, wedge-based binding mechanism[@R50]. Thus, non-enzymatic nucleotide flipping emerges as a surprisingly general mechanism to channel specific base damage into the general damage NER pathway by handoff from a non-enzymatic complex.

Methods Summary {#S6}
===============

Atl1 purification, crystallization, X-ray diffraction data collection, and structural refinement {#S7}
------------------------------------------------------------------------------------------------

C-terminally 6x-His tagged Atl1 was expressed in JM109 cells and purified over Ni-NTA agarose and Superdex 75 columns. Atl1:*O*^6^-mG- and Atl1:*O*^6^-pobG-DNA complexes were prepared at a 1.5:1 DNA:protein molar ratio. Crystals were grown by hanging drop vapor diffusion. Diffraction data were collected at ALS beamline 12.3.1 for Atl1 and at SSRL beamline 11-1 for Atl1:*O*^6^-mG and Atl1:*O*^6^-pobG DNA complexes, and were processed with HKL2000. Structures were solved by molecular replacement with Phaser, using a modified wild-type Ada-C (PDB code 1SFE) as a search model for Atl1, and the refined Atl1 structure as a search model for Atl1:DNA complexes. Crystallographic refinement was done with Crystallography & NMR System (CNS), and Xfit was used for manual model building.

DNA binding by Atl {#S8}
------------------

Oligonucleotide-Atl1 interactions were analyzed by electrophoretic mobility shift assay using standard methods and by surface plasmon resonance with biotinylated *O*^6^-mG-, *O*^6^-pobG-, or AP-site-containing or control oligonucleotides immobilized on a streptavidin-coated surface of a Biacore SA chip and serial dilutions of Atl1 applied to the cell. DNA complex stoichiometries formed under protein saturation conditions were established by sedimentation equilibrium analysis.

Other biochemical assays {#S9}
------------------------

AGT inhibition assays performed as described previously. Far western analyses performed by standard methods.

Atl1 expression in *S. pombe* {#S10}
-----------------------------

*S. pombe* strains originated from GM4 (*h^−^ atl1::ura4 ura4-D18 leu1-32 his7-366 ade6-M210*), RO131 (*h^+^ rad13::kanMX ura4-D18 his3-D1*). MNNG sensitivity determined by agar plate and clonogenic assays. Mutation rates determined as reversions of *ade6-485* to Ade^+^.

Atl1 expression in *E. coli* {#S11}
----------------------------

pQE-30 empty vector was expressed in *E. coli* GWR109 *ada*^−^ *ogt*^−^ and pQE-30 or pQE-Atl1 in *E. coli* GWR109 *ada*^−^ *ogt*^−^ *atl*^−^. Mutation frequencies determined as number of MNNG-induced Rifampicin resistant mutants (Rif^R^) per 10^8^ surviving cells.

**Full Methods** and any associated references are available in the [Supplementary Information](#SD1){ref-type="supplementary-material"} of the online version of the paper at [www.nature.com/nature](http://www.nature.com/nature).
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![Atl1 structure and lesion-binding site\
**a**, Overlay of Atl1 (yellow) and AGT (cyan; pdb 1EH6) models and comparison of key functional residues. *2F~o~*-*F~c~* electron density (blue) for Atl1 with the binding site Trp56 side chain omitted. **b**, Atl1 (magenta) bound to DNA containing *O*^6^-mG (orange). *2F~o~*-*F~c~* simulated annealing composite omit map (blue) shown for DNA. **c** and **d**, Atl1 lesion-binding site close-up with *O*^6^-pobG (**c**) or *O*^6^-mG (**d**). Amino acid side chains (ball-and-stick) and hydrogen bonds to the damaged guanine (green dashes) show the damage binding.](nihms111565f1){#F1}

![Atl1 DNA binding and damage sculpting\
**a**, Overlay of DNA-free (yellow) and DNA-bound (magenta) Atl1 with the hAGT C-terminal domain (cyan). The rotated *O*^6^-mG (center, spheres) is shown with the binding site loop that determines the open or closed conformation of Atl1. **b**, Atl1 molecular surface revealing an "open" state. **c**, DNA-bound Atl1 molecular surface showing the protein "closed" state. **d**, Atl1-DNA interaction schematic.](nihms111565f2){#F2}

![Atl1 DNA lesion binding affinity and stoichiometry\
**a**, Atl1 binding and dissociation for oligonucleotides containing *O*^6^-mG (top), *O*^6^-pobG (center), or abasic site (bottom). **b**, Gel-shift assays for Atl1 binding normal and *O*^6^-mG 13mer dsDNA (left) and associated *O*^6^-mG DNA binding isotherm analysis (right) showing two independent experiments (●,■). **c**, Sedimentation equilibrium data for *O*^6^-mG 13mer dsDNA complexes (left) and normal 26mer dsDNA (right). Small, randomly distributed residuals (top panels) indicate models in which free protein, DNA, and one protein-DNA complex equilibrate in solution. Calculated stoichiometries are 1.15 ± 0.08 for *O*^6^-mG ds13mer and 3.03 ± 0.20 for normal ds26mer.](nihms111565f3){#F3}

![Biochemical and genetic connection of Atl1 to NER\
**a--b**, Coomassie-stained gel (left) and far-western blot (right) probed with FLAG-eAtl **(a)** or FLAG-UvrA **(b)**. **c**, MNNG-induced (top) and spontaneous (bottom) mutations of wild-type, Δ*atl1*, Δ*rad13* and Δ*atl1* Δ*rad13 S. pombe* strains. **d**, Atl1 and Rad13 are epistatic for MNNG toxicity. Serial dilutions of wild-type, Δ*atl1*, Δ*rad13* and Δ*atl1* Δ*rad13 S. pombe* cells spotted on yeast extract (YE) plates or YE plates containing 0.08 µg/ml MNNG. Results shown are mean ± s.d.; n ≥ 3. **e--h**, Clonogenic assay, revealing Atl1 is epistatic for MNNG toxicity with Rad13 **(e)** and Swi10 **(f)**, but not Rhp14 **(g)** or Rad2 **(h)**. Results shown are mean ± s.e.m; n ≥ 3.](nihms111565f4){#F4}

![Alkyl-G lesion recognition allows NER repair of relatively non-distorting base lesions\
The distorted, stable ATL-DNA complex creates a platform to recruit NER enzymes to *O*^6^alkyl-G lesions. This general model is based upon our combined structural, biochemical and genetic results.](nihms111565f5){#F5}
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